- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Benjamin Comer
Benjamin Comer bio
Ben Comer is senior editor at Pharmaceutical Executive. Prior to joining PE, he worked as a reporter for several years at Haymarket Media's Medical Marketing & Media magazine, covering professional and consumer pharmaceutical marketing strategy and tactics, traditional and digital media, and U.S. regulatory policy. Ben is a licensed but no-longer-practicing pharmaceutical technician, and a voracious reader. In 2005, he received an undergraduate degree in journalism and media studies from the College of Charleston, South Carolina, and taught an English language class in Zhuji, China, in 2004, though he unfortunately speaks very little Mandarin. Ben’s reportage at Medical Marketing & Media (MM&M) has been published variously in aggregate online, and his work has also appeared in PR Week and Direct Marketing News, sister titles to MM&M, and most recently the Green Hills News, a local newspaper in Nashville, Tennessee. Aside from journalistic endeavors, Ben has worked as a boom operator on independent films in the New York City area, a bike courier (very briefly), a screenwriter (unpaid), and an unpublished fiction writer.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
What Every Pharma CEO Should Know About Unlocking Scientific Data Potential
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
